Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges

被引：7
作者：
Allard, Camille [1 ]
Cota, Daniela [1 ]
Quarta, Carmelo [1 ]
机构：
[1] Univ Bordeaux, INSERM, Neuroctr Magendie, U1215, F-33000 Bordeaux, France
来源：
DRUGS | 2024年 / 84卷 / 02期
关键词：
GLUCAGON-LIKE PEPTIDE-1; GASTRIC-INHIBITORY POLYPEPTIDE; GLP-1 RECEPTOR AGONISTS; ADIPOSE-TISSUE THERMOGENESIS; ONCE-WEEKLY SEMAGLUTIDE; DIET-INDUCED OBESE; FOOD-INTAKE; WEIGHT-LOSS; BODY-WEIGHT; GLYCEMIC CONTROL;
D O I：
10.1007/s40265-023-01982-6
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The use of glucagon-like peptide-1 (GLP-1) receptor-based multi-agonists in the treatment of type 2 diabetes and obesity holds great promise for improving glycaemic control and weight management. Unimolecular dual and triple agonists targeting multiple gut hormone-related pathways are currently in clinical trials, with recent evidence supporting their efficacy. However, significant knowledge gaps remain regarding the biological mechanisms and potential adverse effects associated with these multi-target agents. The mechanisms underlying the therapeutic efficacy of GLP-1 receptor-based multi-agonists remain somewhat mysterious, and hidden threats may be associated with the use of gut hormone-based polyagonists. In this review, we provide a critical analysis of the benefits and risks associated with the use of these new drugs in the management of obesity and diabetes, while also exploring new potential applications of GLP-1-based pharmacology beyond the field of metabolic disease.
引用
收藏
页码：127 / 148
页数：22
相关论文
共 234 条
[61]   Liraglutide [J].
Drucker, Daniel J. ;
Dritselis, Argyris ;
Kirkpatrick, Peter .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (04) :267-268
[62]   The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets [J].
El, Kimberley ;
Douros, Jonathan D. ;
Willard, Francis S. ;
Novikoff, Aaron ;
Sargsyan, Ashot ;
Perez-Tilve, Diego ;
Wainscott, David B. ;
Yang, Bin ;
Chen, Alex ;
Wothe, Donald ;
Coupland, Callum ;
Tschoep, Mattias H. ;
Finan, Brian ;
D'Alessio, David A. ;
Sloop, Kyle W. ;
Mueller, Timo D. ;
Campbell, Jonathan E. .
NATURE METABOLISM, 2023, 5 (06) :945-+
[63]  
emolecules, about us
[64]   Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial [J].
Enebo, Lone B. ;
Berthelsen, Kasper K. ;
Kankam, Martin ;
Lund, Michael T. ;
Rubino, Domenica M. ;
Satylganova, Altynai ;
Lau, David C. W. .
LANCET, 2021, 397 (10286) :1736-1748
[65]  
ENG J, 1992, MT SINAI J MED, V59, P147
[66]  
ENG J, 1992, J BIOL CHEM, V267, P7402
[67]   Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus [J].
Faillie, Jean-Luc ;
Yu, Oriana H. ;
Yin, Hui ;
Hillaire-Buys, Dominique ;
Barkun, Alan ;
Azoulay, Laurent .
JAMA INTERNAL MEDICINE, 2016, 176 (10) :1474-1481
[68]   Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes [J].
Finan, Brian ;
Capozzi, Megan E. ;
Campbell, Jonathan E. .
DIABETES, 2020, 69 (04) :532-541
[69]   Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease [J].
Finan, Brian ;
Clemmensen, Christoffer ;
Zhu, Zhimeng ;
Stemmer, Kerstin ;
Gauthier, Karine ;
Mueller, Luisa ;
De Angelis, Meri ;
Moreth, Kristin ;
Neff, Frauke ;
Perez-Tilve, Diego ;
Fischer, Katrin ;
Lutter, Dominik ;
Sanchez-Garrido, Miguel A. ;
Liu, Peng ;
Tuckermann, Jan ;
Malehmir, Mohsen ;
Healy, Marc E. ;
Weber, Achim ;
Heikenwalder, Mathias ;
Jastroch, Martin ;
Kleinert, Maximilian ;
Jall, Sigrid ;
Brandt, Sara ;
Flamant, Frederic ;
Schramm, Karl-Werner ;
Biebermann, Heike ;
Doering, Yvonne ;
Weber, Christian ;
Habegger, Kirk M. ;
Keuper, Michaela ;
Gelfanov, Vasily ;
Liu, Fa ;
Koehrle, Josef ;
Rozman, Jan ;
Fuchs, Helmut ;
Gailus-Durner, Valerie ;
de Angelis, Martin Hrabe ;
Hofmann, Susanna M. ;
Yang, Bin ;
Tschoep, Matthias H. ;
DiMarchi, Richard ;
Mueller, Timo D. .
CELL, 2016, 167 (03) :843-+
[70]   A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents [J].
Finan, Brian ;
Yang, Bin ;
Ottaway, Nickki ;
Smiley, David L. ;
Ma, Tao ;
Clemmensen, Christoffer ;
Chabenne, Joe ;
Zhang, Lianshan ;
Habegger, Kirk M. ;
Fischer, Katrin ;
Campbell, Jonathan E. ;
Sandoval, Dar Leen ;
Seeley, Randy J. ;
Bleicher, Konrad ;
Uhles, Sabine ;
Riboulet, William ;
Funk, Jurgen ;
Hertel, Cornelia ;
Belli, Sara ;
Sebokova, Elena ;
Conde-Knape, Karin ;
Konkar, Anish ;
Drucker, Daniel J. ;
Gelfanov, Vasily ;
Pfluger, Paul T. ;
Muller, Timo D. ;
Perez-Tilve, Diego ;
DiMarchi, Richard D. ;
Tschop, Matthias H. .
NATURE MEDICINE, 2015, 21 (01) :27-36
234567891011